1.
A comparison of efficacy between recombinant activated factor VII (ARYOSEVEN TM) and NOVOSEVEN® in patients with hereditary FVIII deficiency with inhibitor
Faranoush M, Abolghassemi H, Toogeh G, Karimi M, Eshghi P, Managhchi M, Hoorfar H, Keikhaei DB, Mehrvar B, Khoein B, et al
Blood. 2014;124((21)): Abstract No. 4299
2.
Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura
Shahgholi E, Vosough P, Sotoudeh K, Arjomandi K, Ansari S, Salehi S, Faranoush M, Ehsani MA
Indian Journal of Pediatrics. 2008;75((12):):1231-5.
Abstract
OBJECTIVE The purpose of this study was to compare the efficacy and side effects of intravenous immunoglobulin (IVIG) with intravenous anti-D immunoglobulin for treatment of newly diagnosed acute childhood Idiopathic thrombocytopenic purpura (ITP). METHODS Children (6 months to 14 years) with newly diagnosed acute ITP and platelet count below 20,000/ microL were randomized to receive single dose intravenous 75 microg/kg anti-D or 1g/kg IVIG for two consecutive days (total dose 2 g/kg). Response rate defined as a platelet count over 20,000 / microL 72 hours after initial treatment. RESULTS Eighty one patients (52 male and 29 female) with mean age of 5 years and 3 months randomly divided in anti-D group (n=42) and IVIG group (n=39). Mean baseline (pretreatment) platelet counts were 15406 / microL and 15230/ microL in anti-D and IVIG group, respectively. The response rate in IVIG group (98%) was more significant than anti-D group (76%); (P = 0. 017). After 7 days the platelet counts of all patients in IVIG group were more than 20,000/ microL while in anti-D group 12% had platelet counts below 20,000/ microL. CONCLUSION In acute childhood ITP, initial treatment with IVIG (2g/Kg in divided dose) increased platelet count more rapidly and more significant than intravenous anti-D (single dose of 75 microg/kg) within the first 72 hours.